Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07442149 · ClinicalTrials.gov registry record · Phase 1
An Investigational Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of A-005
A Phase 1 study, sponsored by Alumis.
- Completed
- Registry status
- Phase 1
- Development phase
- 135
- Enrollment target
NCT07442149 is a Phase 1 study that has completed, run by Alumis. The registered enrollment target is 135 participants.
The verdict
NCT07442149, a Phase 1 study, has completed, sponsored by Alumis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 135 participants
- Enrollment target
Study Summary
This is a 3-part study. Parts A and B are randomized, double-blind, placebo-controlled, multi-cohort investigations to assess the safety, PK, and PD of single ascending doses (SAD; Part A) and multiple ascending doses (MAD; Part B) of orally-administered A-005. Part C is optional and will be an open-label, one-cohort, single dose study to assess the penetration of orally-administered A-005 into the CSF (Cerebrospinal fluid).
Interventions
- DRUG Placebo
- DRUG A-005
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2024-04-22 |
| Est. Completion | 2024-12-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07442149
The ClinicalTrials.gov registry entry for NCT07442149 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 135 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alumis, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07442149 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07442149 about?
NCT07442149 is a clinical study titled "An Investigational Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of A-005". This is a 3-part study. Parts A and B are randomized, double-blind, placebo-controlled, multi-cohort investigations to assess the safety, PK, and PD of single ascending doses (SAD; Part A) and multiple ascending doses (MAD; Part B) of orally-administered A-005. Part C is optional and will be an open...
What is the current status of trial NCT07442149?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 135 participants. The study started on 2024-04-22. Estimated completion is 2024-12-18.
What interventions are being tested in trial NCT07442149?
The interventions under investigation include: Placebo (DRUG), A-005 (DRUG).
Who is sponsoring clinical trial NCT07442149?
This trial is sponsored by Alumis, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.